



thetrutides

WOLVERINE BLEND

BPC-157 + TB-500 — the recovery pairing

UPDATED 4 AUGUST 2026

The most requested combination in the recovery category, pairing the most-studied healing peptide in animal research with a thymosin fragment. Both components were recommended by the FDA advisory committee in July 2026 — and both still carry real evidence gaps worth understanding before you buy.

● In Plain English

This is the pairing people mean when they talk about a “recovery stack”. The logic is that two repair signals working through different routes should do more together than either alone. That logic is reasonable and it is also untested — no study has examined the two administered together, so the combination rationale is inference rather than evidence.

What people use it for. This is the recovery stack — injuries, joint and tendon issues, and general repair after hard training. It is the most requested combination in the range.

What to know before you buy. Two things. First, the two components sit at very different evidence levels: BPC-157 has three decades of animal work behind it, TB-500 has almost nothing of its own. Second, if you are also considering GLOW or KLOW, be aware they both already contain BPC-157 and TB-500. Running Wolverine on top of either one just doubles the same two peptides rather than adding anything. Pick one, do not layer them.

● What It's Used For

GOAL	WHAT THAT RESTS ON
Injury and strain recovery	The most requested recovery pairing; BPC-157 brings the deepest animal literature in the category
Tendon and joint support	Improved healing across multiple animal injury models for BPC-157
Training recovery	Two repair signals acting through separate mechanisms
Convenience	One vial instead of two, at the ratio most people run anyway

The left column lists goals people commonly pursue with this compound; the right column states what that rests on. These are described uses and research findings, not proven outcomes or treatment claims. Individual results vary and no outcome is promised.



● Pricing & Sizes

PRICING

20mg vial (10mg + 10mg)

\$95

Bulk pricing: 2-3 vials -5% | 4-6 vials -10% | 7-9 vials -15% | 10+ vials -20%

Ships sealed and lyophilized — stable for years at room temperature, reconstitute before use, or ask and it will be reconstituted free at the volume shown below. **Free shipping on every order, no minimum.** Third-party COA available for every batch — HPLC purity and mass spec verification.

Reconstitution — bacteriostatic water: 20mg vial at 2mL = 10mg/mL, so 10 units on a 100-unit syringe draws 1mg. Concentrations are arithmetic from vial content and diluent volume, not a dosing recommendation.

Bought separately, BPC-157 10mg is **\$48**. Wolverine is **\$95** and adds 10mg of TB-500, which is not sold as a standalone vial.

● Also Available in These Blends

BLENDS CONTAINING WOLVERINE BLEND

GLOW 70mg — adds GHK-Cu

\$100

KLOW 80mg — adds GHK-Cu + KPV

\$110

Bulk pricing: 2-3 vials -5% | 4-6 vials -10% | 7-9 vials -15% | 10+ vials -20%

Same peptide, supplied alongside others in a single vial. **Ships sealed and lyophilized** — stable for years at room temperature, reconstitute before use, or ask and it will be reconstituted free at the volume shown below. **Free shipping on every order, no minimum.** Third-party COA available for every batch — HPLC purity and mass spec verification.

● At a Glance

COMPONENTS	BPC-157 and TB-500, typically at a 1:1 ratio
RATIONALE	Two repair signals acting through different mechanisms — angiogenesis and growth factor modulation (BPC-157) alongside actin regulation and cell migration (TB-500)
EVIDENCE	BPC-157 has an extensive animal literature; TB-500 has essentially none of its own. The blend as a combination has never been formally studied
REGULATORY (US)	Neither component is FDA-approved. Both were recommended for 503A listing on 23 July 2026; no FDA action has been taken on either
FORMAT	20mg vial (10mg + 10mg)

2

ACTIVE PEPTIDES

8-6-1

PCAC VOTE, BOTH

0

STUDIES OF THE BLEND

REGULATORY STATUS — READ THIS FIRST

On 23 July 2026 the FDA Pharmacy Compounding Advisory Committee voted **8-6-1 to recommend** both BPC-157 and TB-500 for the Section 503A bulk drug substances list. That vote is **advisory only**. As of 4 August 2026 the FDA has taken no action on it, has not opened rulemaking, and has not moved the substance to the interim Category 1 list. FDA's own scientific reviewers had recommended *against* all seven peptides; the committee voted against staff on six consecutive votes, so the usual assumption that a PCAC recommendation predicts the agency's decision is weaker here than normal. Several outlets have reported this as the FDA "clearing", "approving" or "adding" these peptides to the bulks list. That is inaccurate. Nothing has been added and nothing is legally cleared.

● How the Components Compare

Each component brings something the others do not — and each has gaps the others fill. This is what is actually in the vial, stated plainly:

COMPONENT	WHAT IT ADDS	WHAT IT DOES NOT DO
BPC-157	The deepest evidence base of the pair — 100+ animal studies across tendon, ligament, muscle, gut, skin and bone. Also the only one of the two with any gut application	Does not address skin, collagen or inflammation directly. No completed human trial
TB-500	Adds a separate repair mechanism — cell migration and tissue remodelling rather than angiogenesis, so it is complementary rather than duplicative	Has no direct research of its own; supporting work belongs to the larger parent protein. Nothing for inflammation or skin

● What You Are Actually Buying

The two components sit at very different points on the evidence scale, and a blend sheet that averages them would be misleading. Read them separately:

COMPONENT	EVIDENCE POSITION	MAIN CAVEAT
BPC-157	100+ animal studies over three decades; 1 of 36 published studies involved humans	No completed randomised controlled trial; first controlled human trial began recruiting 2026
TB-500	FDA stated at the hearing that there are no studies on TB-500 itself	Supportive research belongs to Tβ4, a larger protein; vendor sequences vary; unresolved theoretical cancer question

SOURCING NOTE

Because "TB-500" is a common name rather than a defined substance, the COA matters more for this blend than for most. Verify the stated sequence and molecular weight for the TB-500 component specifically, not just the total peptide content.

● Stacking Consideration

Wolverine overlaps directly with the GLOW and KLOW blends, both of which also contain BPC-157 and TB-500. Running Wolverine alongside either one doubles those two components rather than adding anything new. If you are moving between them, replacing is cleaner than stacking — both for dose control and because it keeps the variable clean if you are trying to judge what is working.

THE BOTTOM LINE

A plausible pairing built from one component with a deep animal literature and one with almost no direct evidence at all. The July 2026 PCAC recommendation improves the odds of an eventual legal compounding pathway; it says nothing about whether the combination works.

Research use only. Products referenced in this document are supplied for laboratory and research purposes only and are **not for human or veterinary consumption**, not for diagnostic use, and not for use in food or cosmetics. They are not sold as drugs, dietary supplements or medical devices. **Not medical advice.** This document summarises publicly available research and is provided for informational and educational purposes only. It is not medical advice, not a diagnosis, not a treatment recommendation, and not an offer or promise to treat, cure, mitigate or prevent any disease or condition. Nothing here should be relied upon in place of advice from a qualified, licensed healthcare professional, and you should consult one before making any health decision. **On the statements made here.** Descriptions of research findings summarise what published studies have reported. They are not claims of safety or efficacy, and they should not be read as representing that any outcome will occur. Where research is preclinical (cell or animal), findings may not translate to humans. Individual results vary, and no particular result is promised or implied. Unless expressly stated otherwise, compounds described here are **not approved by the FDA** for any indication. **Regulatory information.** Regulatory positions described are current as of the date of this document and are subject to change without notice; verify current status independently before relying on it. **Buyer responsibility.** Purchasers are responsible for determining the lawfulness of purchase, possession and use in their jurisdiction. **No warranty.** This information is provided "as is" without warranty of any kind, express or implied. To the fullest extent permitted by law, no liability is accepted for any loss or damage arising from reliance on it. **Pricing.** Prices shown are current as of the date of this document, are subject to change without notice, and do not constitute a binding offer. **Sources:** FDA PCAC meeting materials and briefing documents, 23-24 July 2026; Hyman, Phelps & McNamara FDA Law Blog, 24 and 28 July 2026; Mintz, 29 July 2026; Polsinelli, 22 April 2026.